A multicenter, double-blinded, randomised, 12 month, parallel group study to compare the efficacy of 48 mg BETahistine versus 8 [three times per day, tid] in the treatment of vertigo attacks in MENière's disease.

Prof. Dr. P.P.G. van Benthem (November 2015)Functie/ Position: Hoogleraar Keel-, neus-, oorheelkunde │Opleiding/Education: Studierichting/ Subject:T: +31 55 844 8207 │ F: +31 55 581 8194 │E: p.van.benthem@gelre.nl Prof. Dr. P.P.G. van Benthem (november 2015)University Medical Centre LeidenHead Otorhinolaryngolgy and Head- and Neck Surgery P.O. Box 96002300 RC Leiden0 sites74 target enrollmentTBD

Overview

Brief Summary

ot applicable

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

Prof. Dr. P.P.G. van Benthem (November 2015)Functie/ Position: Hoogleraar Keel-, neus-, oorheelkunde │Opleiding/Education: Studierichting/ Subject:T: +31 55 844 8207 │ F: +31 55 581 8194 │E: p.van.benthem@gelre.nl Prof. Dr. P.P.G. van Benthem (november 2015)University Medical Centre LeidenHead Otorhinolaryngolgy and Head- and Neck Surgery P.O. Box 96002300 RC Leiden

Eligibility Criteria

Inclusion Criteria

•1\. Unilateral MD (definite or probable) according to diagnostic criteria derived from the American Academy Otolaryngology Head and Neck Surgery, Classification Committee of the Bárány Society, European Academy of Otology and Neurotology and International Classification of Vestibular Disorders published in 2015\.
•2\. Age \> 18 years at the start of the trial.

Exclusion Criteria

•1\.Bilateral MD.
•2\.Severe disability (e.g. neurological, orthopedic, cardiovascular) or serious concurrent illness that might interfere with treatment or follow\-up.